Martin K. Gelbard, MD
Assistant Clinical Professor, Department of Urology
University of California, Los Angeles
Los Angeles, California
Content Planning Committee:
Gerald H. Jordan, M.D., F.A.C.S., F.A.A.P. (Hon)
Professor, Department of Urology
Eastern Virginia Medical School
Director, Devine Center for Genitourinary Reconstruction
Sentara Norfolk General Hospital
Wayne Hellstrom, M.D., F.A.C.S.
Professor of Urology
Chief of Andrology
Tulane University School of Medicine
New Orleans, Louisiana
Originally presented as a live CME educational symposium held in conjunction with the American Urological Association’s Southeastern Section meeting in San Diego, CA on March 6, 2008. If you received CME credit for the live event, you are not eligible to receive credit for this online release.
Peyronie's disease is an acquired fibromatosis involving the corpora cavernosa and may cause fibrotic, nonexpansive thickening of discrete areas of the corpora tunica, resulting in focal bend, pain or other functional abnormalities of the erect penis. Men with Peyronie's disease typically have difficulty with coitus as a result of penile curvature. In many patients, the lesion is painless and progresses very slowly or not at all. Nonsurgical treatment options currently remain very limited, but investigational treatment options may eventually offer safe and effective options for many patients. Nonsurgical options may be systemic in nature (eg, oral preparations such as vitamin E, POTABA, colchicines, tamoxifen, carnitines, pentoxyphylline, or PDE-5s), topical (eg, verapamil), extracorporeal (traction, ESW or radiation) or intralesional (eg, verapamil, collagenase, or interferon). At present, surgery is the only approved treatment for Peyronie’s disease and may represent an optimal first choice for certain patients. Combining two therapies may also represent a therapeutic option. Program Developer/Facilitator
. Target Audience
This educational activity is designed to meet the educational needs of urologists.
Upon completion of this educational activity, the participant should be able to:
Review the epidemiology and pathophysiology of Peyronie’s disease.
Discuss patient assessment and appropriateness of therapy for common presentations of the disease.
List and describe available and investigational topical, oral, and intralesional treatment options for Peyronie’s disease.
Evaluate clinical trial data for agents used in the management of Peyronie’s disease.
Determine which patients should be referred for surgery and when.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Martin K. Gelbard, MD discloses that he is a member of a speakers bureau for Pfizer Inc, is on an advisory committee for Auxilium Pharmaceuticals, and owns common stock of Pfizer Inc, and Auxilium Pharmaceuticals.
Gerald H. Jordan, MD, FACS., FAAP (Hon) discloses that he is a board member with Engineers & Doctors A/S, has royalty or property rights with C & S Surgical, is a member of speakers bureaus with Auxilium Pharmaceuticals and American Medical Systems, is a product consultant for Coloplast and American Medical Systems, and is on an advisory committee for Auxilium Pharmaceuticals.
Wayne Hellstrom, M.D., F.A.C.S. discloses that he is a member of an advisory committee for Auxilium Pharmaceuticals.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit is awarded to participants who score 70% or better on the post-test. One retake is allowed. A statement of credit can be printed following successful completion. This activity should take approximately 60 minutes to complete.
Commercial Support Statements
Supported through an educational grant from Auxilium Pharmaceuticals.
©2008, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this activity are those of the presenter and do not necessarily reflect the opinions or recommendations of his affiliated institution, the publisher, AKH Inc., the American Urological Association, or Auxilium Pharmaceuticals, Inc. Any medications or other diagnostic or treatment procedures discussed by the program faculty should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.